FDA Brief

Warning letters Drugs

FDA warning letter to

Omni Lens Pvt. Ltd.

High riskIssued Oct 2, 2024Posted Oct 22, 2024Center for Drug Evaluation and Research (CDER)

FDA warns Omni Lens about CGMP failures and misbranding of ophthalmic OTC drugs made by unregistered contract manufacturers.

What happened

FDA reviewed records Omni Lens submitted in response to the agency's November 21, 2023, and April 5, 2024, requests under section 704(a)(4) of the FD&C Act. FDA found significant current good manufacturing practice (CGMP) violations: the firm lacked an adequate quality unit (the group responsible for quality oversight), delegated quality responsibilities to contract manufacturers, and did not adequately oversee a contract manufacturer whose aseptic processing room for ophthalmic drops was inadequately designed and lacked dynamic airflow visualization studies and specified effectiveness testing for benzalkonium chloride. FDA also found that Green Glo, BioGlo, and Vista Gonio Eye Lubricant were made at establishments not duly registered with FDA, making them misbranded (legally mislabeled).

What FDA found

  1. The quality control unit failed to ensure drug products complied with CGMP and met established specifications for identity, strength, quality, and purity.

    21 CFR 211.22
  2. The firm lacked an adequate quality unit and delegated its quality-unit responsibilities to contract manufacturers, leaving insufficient oversight of their CGMP compliance.

    21 CFR 211.22
  3. Its contract manufacturer lacked an adequately designed aseptic processing (sterile manufacturing) room for ophthalmic drop products and had not performed dynamic airflow visualization studies for aseptic processing.

    21 CFR parts 210 and 211
  4. The firm had not performed (b)(4) effectiveness testing for benzalkonium chloride-containing ophthalmic products.

    21 CFR parts 210 and 211
  5. Green Glo, BioGlo, and Vista Gonio Eye Lubricant were manufactured at establishments that were not duly registered with FDA, so they are misbranded.

    FD&C Act §502(o); §510; 21 U.S.C. 352(o), 360

What FDA wants

FDA tells Omni Lens to correct the violations promptly and respond in writing within 15 working days with corrective actions and a quality-unit assessment/remediation plan. FDA also says it may withhold approvals and continue refusing admission while the firm remains on Import Alert 66-40.

Who should pay attention

  • brands that use Omni Lens or its contract manufacturers for ophthalmic OTC drugs
  • distributors and importers of Green Glo, BioGlo, or Vista Gonio Eye Lubricant
  • companies relying on contract manufacturers for sterile ophthalmic products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk